Emergent BioSolutions’ ACAM2000 receives FDA approval for Mpox prevention
Emergent BioSolutions Inc. (NYSE: EBS) has achieved a notable milestone with the U.S. Food and Drug Administration (FDA) approving the supplemental Biologics License Application (sBLA) ... Read More
Emergent’s Narcan nasal spray receives OTC nod for opioid overdose treatment
Emergent BioSolutions’ Narcan nasal spray has secured over-the-counter (OTC) designation from the US Food and Drug Administration (FDA), becoming the first and only prescription strength ... Read More
Bavarian Nordic to acquire Vivotif and Vaxchora travel vaccines from Emergent BioSolutions
Bavarian Nordic A/S will acquire two oral vaccines from Emergent BioSolutions for a total consideration of up to $380 million, to strengthen its position in ... Read More
Emergent BioSolutions begins phase 3 trial of CHIKV VLP vaccine candidate
Emergent BioSolutions said that it has dosed the first participant in a phase 3 clinical trial of CHIKV VLP — the company’s single-dose chikungunya vaccine ... Read More